Acute Lymphoblastic Leukemia(T-ALL)-10

A 13-year-old boy named Yangyang from Panzhihua, Sichuan Province, underwent CAR-T followed by bridging transplantation.

Yangyang presented initially with "scattered bruises throughout the body accompanied by fatigue" on April 12, 2021. He was diagnosed with acute lymphoblastic leukemia (T-cell subtype) with intracranial hemorrhage and lung infection confirmed by bone marrow MICM examination at a large hospital in Chongqing. He underwent 3 cycles of chemotherapy at another hospital, but bone marrow did not respond. By early June, he developed weakness in both lower limbs and could not walk.

On July 1, 2021, Yangyang was admitted to our Hematology Department Ward 2. He enrolled in the CD7 CAR-T clinical trial on July 8 and received autologous CD7 CAR-T cell infusion on July 26 for immunotherapy. Sixteen days after infusion, bone marrow morphology showed remission, and flow cytometry indicated 0.07% suspicious malignant immature T lymphoblasts. After physical therapy, he regained the ability to walk independently. By day 31 post-infusion, his bone marrow achieved complete remission.

Currently, Yangyang has been transferred to Ward 6 of the Bone Marrow Transplantation Department for further treatment. Dr. Hai from Ward 6 stated that Yangyang has been actively cooperative and optimistic throughout his treatment. He underwent allogeneic hematopoietic stem cell transplantation (from his father) on September 28. The conditions created by the Hematology Department colleagues for his bridging transplantation were greatly appreciated.

These patients, prior to enrollment in the CD7 CAR-T clinical trial, presented with various symptoms such as post-transplant relapse, T/myeloid dual expression, refractory/resistant acute T-cell leukemia, central nervous system leukemia, intracranial hemorrhage, and lung infection. After assessment and treatment with CD7 CAR-T therapy, all achieved complete remission, meeting expected outcomes.

Ludaopei Hospital has actively explored in the field of CAR-T therapy and accumulated rich experience in managing CRS. For most participants, the most severe side effect was high fever. "I can achieve complete remission, so the fever is nothing! I want more people to know that Ludaopei can do CAR-T!" said Yangyang from Fujian upon discharge.